Our top pick for
Innospec Inc is a specialty chemicals business based in the US. Innospec shares (IOSP) are listed on the NASDAQ and all prices are listed in US Dollars. Innospec employs 1,900 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$85.70|
|52-week range||$61.20 - $107.15|
|50-day moving average||$88.16|
|200-day moving average||$94.07|
|Wall St. target price||$112.00|
|Dividend yield||$1.09 (1.27%)|
|Earnings per share (TTM)||$3.25|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||0.63%|
|1 month (2021-09-17)||1.18%|
|3 months (2021-07-16)||-2.75%|
|6 months (2021-04-16)||-16.65%|
|1 year (2020-10-16)||24.60%|
|2 years (2019-10-17)||-7.98%|
|3 years (2018-10-17)||23.06%|
|5 years (2016-10-17)||39.74%|
Valuing Innospec stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innospec's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innospec's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Innospec shares trade at around 26x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Innospec's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $158.7 million.
The EBITDA is a measure of a Innospec's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.3 billion|
|Operating margin TTM||9.19%|
|Gross profit TTM||$342.7 million|
|Return on assets TTM||5.21%|
|Return on equity TTM||8.66%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
There are currently 357,555 Innospec shares held short by investors – that's known as Innospec's "short interest". This figure is 7.6% down from 387,148 last month.
There are a few different ways that this level of interest in shorting Innospec shares can be evaluated.
Innospec's "short interest ratio" (SIR) is the quantity of Innospec shares currently shorted divided by the average quantity of Innospec shares traded daily (recently around 74027.950310559). Innospec's SIR currently stands at 4.83. In other words for every 100,000 Innospec shares traded daily on the market, roughly 4830 shares are currently held short.
However Innospec's short interest can also be evaluated against the total number of Innospec shares, or, against the total number of tradable Innospec shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innospec's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Innospec shares in existence, roughly 10 shares are currently held short) or 0.0147% of the tradable shares (for every 100,000 tradable Innospec shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Innospec.
Find out more about how you can short Innospec stock.
Dividend payout ratio: 25.12% of net profits
Recently Innospec has paid out, on average, around 25.12% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.34% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Innospec shareholders could enjoy a 1.34% return on their shares, in the form of dividend payments. In Innospec's case, that would currently equate to about $1.09 per share.
While Innospec's payout ratio might seem fairly standard, it's worth remembering that Innospec may be investing much of the rest of its net profits in future growth.
Innospec's most recent dividend payout was on 25 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 May 2021 (the "ex-dividend date").
Innospec's shares were split on a 2:1 basis on 22 July 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Innospec shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Innospec shares which in turn could have impacted Innospec's share price.
Over the last 12 months, Innospec's shares have ranged in value from as little as $61.2011 up to $107.145. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innospec's is 1.3413. This would suggest that Innospec's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. It operates through Fuel Specialties, Performance Chemicals, and Oilfield Services segments. The Fuel Specialties segment offers a range of specialty chemical products used as additives in various fuels. Its products are used in the operation of automotive, marine, and aviation engines; power station generators; and heating oil. The Performance Chemicals segment provides technology-based solutions for its customers' processes or products focused in the personal care, home care, agrochemical, and metal extraction markets. The Oilfield Services segment develops and markets products to prevent loss of mud in drilling operations; chemical solutions for fracturing, stimulation, and completion operations; and products for oil and gas production, which enable flow assurance and maintain asset integrity.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.